Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2
3(75.0%)
Phase 1
1(25.0%)
4Total
Phase 2(3)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07312292Phase 2Recruiting

Radioembolization With Intra-arterial Angiotensin II to Improve Tumor-absorbed Dose (RADIANT)

Role: collaborator

NCT00331721Phase 2Terminated

Tolerability of Enecadin (INN) in Acute Ischemic Stroke Trial - TEST

Role: lead

NCT00638781Phase 2Completed

Desmoteplase in Acute Ischemic Stroke (DIAS)

Role: lead

NCT00638248Phase 1Completed

Dose Escalation of Desmoteplase in Acute Ischemic Stroke (DEDAS)

Role: lead

All 4 trials loaded